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S U M M A R Y
This review summarizes current concepts on post-polio syndrome (PPS), a condition that may arise in
polio survivors after partial or complete functional recovery followed by a prolonged interval of stable
neurological function. PPS affects 15–20 million people worldwide. Epidemiological data are reported,
together with the pathogenic pathways that possibly lead to the progressive degeneration and loss of
neuromuscular motor units. As a consequence of PPS, polio survivors experience new weakness,
generalized fatigue, atrophy of previously unaffectedmuscles, and a physical decline thatmay culminate
in the loss of independent life. Emphasis is given to the possible pathogenic role of persistent poliovirus
infection and chronic inﬂammation. These factors could contribute to the neurological and physical
decline in polio survivors. A perspective is then given on novel anti-poliovirus compounds and
monoclonal antibodies that have been developed to contribute to the ﬁnal phases of polio eradication.
These agents could also be useful for the treatment or prevention of PPS. Some of these compounds/
antibodies are in early clinical development. Finally, current clinical trials for PPS are reported. In this
area, the intravenous infusion of normal human immunoglobulins appears both feasible and promising.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Paralytic poliomyelitis is caused by infection with the poliovi-
rus and dates back to the eighteenth Egyptian dynasty (c. 1543–
1292 BC), or earlier. Large epidemics occurred in the early
nineteenth century, but with the introduction of vaccination,
the number of new cases dropped dramatically in the 1960s.
Today, paralytic poliomyelitis has been essentially forgotten, both
by people and the medical community. Nevertheless, large
numbers of individuals who have survived the illness are alive
today in the world. Resisting vaccination efforts, scattered
poliomyelitis cases continue to surface each year in a few
countries. These cases are holding back or hindering the expected
goal of polio eradication.1,2
Abrupt asymmetrical ﬂaccid paralysis is the clinical manifesta-
tion of anterior poliomyelitis, as acute polio may also present with
othermanifestations. After the acute attack, survivors experience a* Corresponding author. Tel.: +39-0332-278309; Fax: +39-0332-260517.
E-mail addresses: antonio.toniolo@uninsubria.it,
antonio.toniolo@ospedale.varese.it (A. Toniolo).
http://dx.doi.org/10.1016/j.ijid.2015.04.018
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).period of neurological and functional recovery followed by a phase
of almost complete stability. During the stability phase, many
patients become over-achievers, working hard both physically and
emotionally to overcome their disabilities.3 In 1875, new
weakness, muscle atrophy, and fatigue occurring years after
poliomyelitis were recognized by the French neurologist Raymond
and his famous peer Jean-Martin Charcot.4 Since the 1970s, a
multitude of cases have been published worldwide, and in the
1980s, post-polio syndrome (PPS) was accepted as a new medical
condition.5,6 Whereas the late consequences of polio (i.e.,
biomechanical decline such as scoliosis, kyphosis, arthrosis, etc.)
can manifest for any survivor of polio,7 PPS (i.e., neurological
decline) may develop in 20–75% of polio survivors, 15 to>60 years
after acute paralytic or non-paralytic disease.8–16
Common manifestations of PPS include central and peripheral
fatigue, muscle atrophy and weakness, musculoskeletal pain, and
new disabilities that may also affect many other body functions
such as respiration, the digestive tract, voiding, and sleep. It is
estimated that there are 15–20 million polio survivors worldwide.
Medicine has been slow to address the morbidity and cost of
chronic disease and the growing number of elderly persons.17
However, today PPS is recognized as the most prevalent disease ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Social Security Disability Insurance (SSDI) program ﬁrst acknowl-
edged the late effects of poliomyelitis in 1987 (http://www.
postpolioinfo.com). Subsequently, PPS was recognized by the
European Parliament,18 and a speciﬁc code for PPS (G14) was
adopted by the International Classiﬁcation of Diseases 2010.19 In
2012, the problems of polio survivors were presented at the
Commonwealth Parliament of Australia20 and in the Italian
Parliament.
In spite of the numbers of affected patients, the aetiology and
pathogenesis of PPS are still unclear and no effective therapy is
available.21 Current treatments are based on a conservative
approach consisting of exercise, avoidance of muscular overuse,
orthoses, and assistive devices (http://www.post-polio.org; http://
www.polioplace.org). Diagnosis is based on the medical history
and clinical–instrumental examination, as well as on the exclusion
of medical conditions other than polio that could explain the
symptoms.22
2. Structure and genome of polioviruses
The three poliovirus (PV) types (PV1, 2, 3) belong to Enterovirus
group C of the Picornaviridae family. Virions are non-enveloped
icosahedral particles, about 28 nm in diameter. As shown in
Figure 1, the genome consists of a single-stranded, positive-sense
RNA of about 7.4 kb, with a 22-aa virus-encoded protein (viral
protein genome-linked, VPg) covalently linked to the 50 end.23 The
50 non-translated region (approximately 740 nt) has a complex
secondary structure consisting of region 1 (regulatory) and region
2 that represents the internal ribosome entry site (IRES). The single
open reading frame encodes a polyprotein of about 2200 amino
acids that is processed to yield four different capsid proteins (viral
proteins VP1, VP2, VP3, and VP4) and seven non-structural
proteins (2A (protease), 2B (endoplasmic reticulum localization,
viroporin), 2C (ATPase, helicase), 3A (Golgi localization), 3B (VPg),
3C (major viral protease), and 3D (RNA-dependent RNA polymer-
ase). The 30 non-translated region contains a variable poly-A tail of
approximately 70 nt.
Recently, human enteroviruses have been re-classiﬁed, based
largely on genome structure (Table 1). Excluding rhinoviruses, the
Enterovirus genus contains four species of human pathogen (A, B,
C, and D). PVs belong to the C species. Humans are the only natural
host of PVs. Many different human cell types express the CD155
poliovirus receptor24 that is essential for infection, possibly
together with a co-receptor. All enteroviruses are quite resistant[(Figure_1)TD$FIG]
Figure 1. Schematic diagram of the poliovirus genome. Structural and non-structural vi
regulates virus replication and plays a fundamental role in the synthesis of viral protein the environment. Transmission occurs through the faecal–oral
route and the respiratory route.
3. Acute poliovirus infection: poliomyelitis
Poliomyelitis is an acute disease caused by infection with any
one of the three PV serotypes. The virus multiplies in the pharynx
and intestine for 1 to 3 weeks. In themajority of cases, virus spread
is contained by the local immune response. Thus, over 95% of
infections are either asymptomatic or characterized by ﬂu-like
symptoms. In 5% of cases, a viraemia phase occurs and virus can
cross the blood–brain barrier by ways that are possibly indepen-
dent from the expression of poliovirus receptor (PVR).24 Upon
arrival in the central nervous system (CNS), patientsmay develop a
meningitis-like illness characterized by fever with pharyngitis,
myalgia, anorexia, nausea, vomiting, headache, and neck stiffness.
The onset of spinal poliomyelitis is associated with myalgia and
severe muscle spasms, with the subsequent development of an
asymmetrical (predominantly lower limb) ﬂaccid weakness that
becomes paretic within a few days.23 A purely bulbar form with
minimal limb involvement may also occur. This form of polio has a
particularly highmortality because of vasomotor disturbances and
other complications (hypertension, hypotension and circulatory
collapse, autonomic dysfunction, dysphagia, dysphonia, and
respiratory failure).
In the epidemics of the last century, most paralytic cases were
attributed to PV1. Epidemics of polio occurred throughout the USA
and Europe, including one severe outbreak from 1943 to 1956 in
which 400 000 people were infected, resulting in 22 000 deaths.
The introduction of Jonas Salk’s inactivated polio vaccine (1955)
and Albert Sabin’s live oral vaccine (1961) dramatically reduced
the number of cases. In 1965, only 61 infections were reported in
the USA and by 1991 the disease had been virtually wiped out in
the Western Hemisphere. The massive MECACAR immunization
program, launched in 1995, started to rapidly clear virus from the
18 countries with residual poliomyelitis, spanning two continents.
In most of the world where the four core eradication strategies
were introduced, the numbers of both cases of polio-paralyzed
children and polio-infected countries began to fall rapidly. The
sense that eradication might soon be inevitable was reinforced in
1999 by the global eradication of type 2 wild poliovirus. This
suggested that the eradication of the other serotypes would follow
quickly in all countries.25
New cases of poliomyelitis due to PV1 and PV3 have now been
reduced to a few hundred per year. In 2014, cases were found in
scattered countries such as Pakistan, Afghanistan, Nigeria, Somalia,rus-coded proteins are indicated. The 50 non-translated genome terminus (50-UTR)
ins.
Table 1
Classiﬁcation of human enteroviruses within the Picornaviridae family (excluding rhinoviruses)
Species
(No. of serotypes)
Serotypes
Enterovirus A (20) CV-A2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16; EV-A71, 76, 89, 90, 91, 114, 119, 120, 121
CV-B1, 2, 3, 4, 5, 6; CV-A9
Enterovirus B (56) E-1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 29, 30, 31, 32, 33; EV-B69, 73, 74, 75, 77, 78, 79, 80, 81,
82, 83, 84, 85, 86, 87, 88, 93, 97, 98, 100, 101, 106, 107, 111
Enterovirus C (13) CV-A-1, 11, 13, 17, 19, 20, 21, 22, 24; EV-C95, 96, 99, 102, 104, 105, 109, 113, 116, 117, 118
PV-1, 2, 3
Enterovirus D (3) EV-D68, 70, 94, 111
CV-A, coxsackievirus group A; CV-B, coxsackievirus group B; E, echovirus; EV-D, enterovirus group D; PV, poliovirus. Modiﬁed from http://www.picornaviridae.com (2015).
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Ethiopia. All of these areas have been affected by war, famine, and
forced humanmigration (http://www.polioeradication.org; date of
consultation: 2015-03-15).
4. Innate and adaptive response to poliovirus infection
In the early phases of infection, the innate response plays a
prominent role.26 Toll-like receptor-3 (TLR3), retinoic acid-
inducible gene 1 (RIG-I), and melanoma differentiation-associated
protein 5 (MDA-5) are the major cytoplasmic receptors of single-
stranded and double-stranded viral RNA. Upon binding of the viral
genome, these sensors activate interferon (IFN) regulatory factor 3,
which is translocated into the nucleus and induces the expression
of type I IFNs. IFNs secreted by infected cells bind to the receptors
of neighbouring cells and activate multiple IFN-stimulated genes
(ISG). Protein kinase R (PKR) and oligoadenylate synthetase 1
(OAS1) inhibit protein synthesis and virus replication, thus
blocking or limiting virus replication and cell damage. In
productively infected cells, PV-coded proteases (2A, 3C) degrade
ISG proteins, PKR, and components of the RIG-I/MDA-5 pathway,
thus curbing the antiviral effect of IFNs.
What has been described above is a dynamic response, thus the
success of limiting local viral replication and virus spread is
dependent on both the rapidity and magnitude of the innate
response. In non-polio enteroviral infections, genetic polymor-
phisms of components of the innate response system decisively
inﬂuence thevirus susceptibilityofmice.27Type I IFNsalsostimulate
the expression of surface major histocompatibility complex class I
(MHC-I) molecules and the activation of natural killer cells, which
are early antiviral effectors. Soon after infection, proinﬂammatory
cytokines and chemokines are secreted by infected and bystander
cells and play a critical role in both inﬂammatory processes and
initiating the adaptive immune response.
Poliovirus infection and vaccination are followed by the
production of neutralizing PV antibodies of the IgM, IgG, and
IgA classes,28 and by the appearance in peripheral blood of CD4
helper T-cells and CD8 cytotoxic/memory T-cells that recognize
viral capsid epitopes.29–31 These cells secrete IFN-g in response to
PV capsid proteins. Neutralizing antisera produced in humans and
animals are type-speciﬁc (i.e., sera against PV1 do not neutralize
PV2 or PV3) and are directed to PV neutralization epitopes that are
conformational and have been described in great detail.32,33 IgM
and IgG antibodies appear 3–4 days after infection. Secretory IgA
becomes detectable 1 week post-exposure.
It has recently become possible to produce human and
chimpanzee neutralizing monoclonal antibodies speciﬁc to each
PV serotype. Monoclonals capable of neutralizing two different
serotypes have also been obtained. These monoclonals bind the
capsid recognition site for the cellular receptor.32,34–36 The
recently obtained antibodies may be of particular value for human
treatment (chronic PV carriers, possible polio epidemics, acciden-
tal exposure to PVs).Anti-poliovirus immunity is protective and life-long. This is also
true for polio victims, but only for the type of PV the victim had.
Thus, vaccination is also advisable for polio survivors. A person is
considered to be fully immunized if he/she has received a primary
series of at least three doses of inactivated poliovirus vaccine (IPV),
live oral poliovirus vaccine (OPV), or four doses of any combination
of IPV and OPV (http://www.cdc.gov/vaccines/vpd-vac/polio/
#vacc).
5. Persistent poliovirus infection in vitro and in vivo
To establish persistent infection, a virus must be able to reduce
its cytopathic effects (i.e., its ability to kill or damage the infected
cell), maintain its genome within host cells over time, and avoid
elimination by the host immune system. Although PVs are
cytolytic to their host cells, mainly due to the shutdown of the
host transcriptional and translational machinery resulting in
substantial inhibition of host cell metabolism,37 some evidence
suggests that persistent PV infection may be associated with
PPS,38–41 as well as with myasthenia gravis.42
A number of in vitro models of PV persistence have been
reported: monkey kidney cells,43 human cells such as the HEp2
line,44 cells of neural and non-neural origin,45 and a neuroblastoma
line.46 Cell cultures persistently infected by PVs show peculiar
characteristics: (1) only a small percentage of cells express viral
antigens, and (2) viral titres (i.e., the amount of infectious viral
particles released by infected cells in the medium) are usually low
(103 plaque-forming units/ml). In persistently infected cultures,
and possibly in vivo, virus spread to uninfected cells is not only
achieved by a lytic mechanism, but also by the release of host cell-
derived microvesicles and the formation of cell protrusions or
intercellular bridges.47–49 The high genetic variation of these
agents (high mutation rate of single-stranded RNA viruses and
recombination events) certainly contributes to the selection of
attenuated variants. In vitro, the possible role of poliovirus
receptor mutations has been documented in neuroblastoma cells
persistently infected with PV.50 Experimental studies in mice have
shown that PV may cause persistent infection and paralysis upon
immunosuppression,51 that infection can be traced to motor
neurons,52 and that hindered replication of the PV genomepossibly
contributes to PV persistence in the CNS.53
Genomic changes in persistent PV isolates (especially in the 50-
untranslated region (50-UTR) and VP1 region) have been reported
in immunodeﬁcient individuals who are chronic carriers of the
virus. In the majority of cases, the persisting virus has been
recovered from the intestine.54–61
Persons with a primary humoral immunodeﬁciency (e.g.,
hypogamma/agammaglobulinemia), or an immunodeﬁciency sec-
ondary to HIV infection or other reasons, may suffer a chronic PV
infection (not only upon infection with wild-type virus, but also
following vaccination with attenuated virus). These individuals
may release large amounts of virus formonths or years.54,57,62–64 In
a study of our group in Italy, persistent PV1 infection of primary
A. Baj et al. / International Journal of Infectious Diseases 35 (2015) 107–116110cultures of human skeletal myoblasts was found to be associated
with the upregulation of pro-inﬂammatory cytokines and chemo-
kines (interleukin (IL)-1, IL-6, IL-8, monocyte chemoattractant
protein 1 (MCP1; manuscript in preparation)). Thus, chronic
infection may be accompanied by the upregulation of cytokines, as
seen in PPS patients.65
6. Diagnostic criteria for PPS
Late functional deterioration after poliomyelitis is common,
and unlike a typical syndrome where signs and symptoms are
relatively constant, this takesmany forms and hasmany causes. No
disabilities are truly static. The causes of late deterioration may
include those related to previous polio (orthopaedic, respiratory,
peripheral nerve entrapment) and those related to subsequent
illness. It is vital to diagnose comorbidities, as many can be
resolved with simple treatment.
There are no diagnostic tests or speciﬁc biomarkers for
PPS.22,66,67 The early diagnostic criteria of Halstead represent
the basis of the criteria presented by Trojan and Cashman68 have
been integrated into current diagnostic guidelines:22 (1) Prior
paralytic poliomyelitis with evidence of motor neuron loss, as
conﬁrmed by history of the acute paralytic illness, signs of residual
weakness, and atrophy of muscles on neurological examination,
and signs of denervation on electromyography. (2) A period of
partial or complete functional recovery after acute paralytic
poliomyelitis, followed by an interval (usually 15 years of more)
of stable neurological function. (3) Gradual or sudden onset of
progressive and persistent muscle weakness or abnormal muscle
fatigability (decreased endurance), with or without generalized
fatigue, muscle atrophy, or muscle and joint pain. Sudden onset
may follow a period of inactivity, or trauma, or surgery. Less
commonly, symptoms attributed to PPS include new problems
with swallowing or breathing. (4) Symptoms persist for at least
1 year. (5) Exclusion of other neurological, medical, and
orthopaedic problems as causes of the symptoms.
Symptoms are often mixed with the physiological changes of
aging (e.g., decreased number of nerve cells, decline in vital
capacity, decline in maximum heart rate and cardiac output,
increased mean systolic blood pressure, decline in bone mineral
mass, altered carbohydrate metabolism, and decline of immune
functions). Health issues for ageing polio survivors and young polio
survivors differ. In young survivors, the challenge is to prevent and
treat severe deformities, to reduce disability, to improve social
participation, and to prevent PPS. In aging polio survivors,Table 2
Reported numbers of polio survivors in different countries and percentages of polio s
population size
Country Population mid-2014
(millions)
No. polio survivors
non-paralytic case
Australia 23.5 400 000
Brazil 202.8 14 0000
Canada 35.5 30 000
Denmark 5.6 12 000
France 64.1 60 000
Germany 80.9 100 000
Italy 61.3 80 000
Japan 127.1 30 000
Norway 5.1 7500
Poland 38.5 30 000
Spain 46.5 45 000
Sweden 9.7 15 000
USA 317.7 640 000
UK 64.5 30 000
Whole world (estimate) 7238.0 15 000 000
PPS, post-poliomyelitis syndrome. Population data: http://www.prb.org/pdf14/2014-wtreatment focuses on the management of PPS and neuromuscular
decline, with the aim of preserving independence and quality of
life.
7. Epidemiology: polio survivors and PPS
There is a growing need for health professionals with the
knowledge to adequately treat the estimated 15–20million people
who have survived polio.69 Polio survivors can be found in every
country around the world, although those in the Western World
tend to belong to an ageing group, whereas those in developing
countries represent the whole age spectrum. For the diagnosis of
PPS, clinicians should not simply require a history of paralytic polio
and electromyographic evidence of denervation, but should also be
aware that non-paralytic polio (and possibly even poliovirus-
induced ‘minor illnesses’) can be associated with CNS damage and
late-onset muscle weakness and fatigue.14,15,70
Data on the numbers of polio survivors per country and
numbers of those who have developed PPS are based mostly on
local estimates and are summarized in Table 2. For many
geographic areas these data are totally missing. Data from polio
associations and/or publications are available for some countries,
including Australia (http://www.polio.org.au/about-polio-
australia/),71,72 Brazil,73,74 Canada,16 Denmark (http://www.
polioplace.org/resources/ptu-danish-society-polio-and-accident-
victims-landsforeningen-af-polio-traﬁk-og-ulykkessk),13 France,75
Germany,76 Italy,77,78 Japan,79 Norway,10 Poland,80 Spain,81
Sweden,82,83 the UK,84 and the USA (http://www.post-polio.org/
ir-usa.html).85 In some countries, the absence of data on the
numbers of polio survivors may reﬂect problems of public health
organizations as well as difﬁculties in conﬁrming the diagnosis of
PPS due to the symptoms being similar to those associated with
natural aging. In fact, case ascertainment is sometimes difﬁcult and
may expose statistics to bias. Taken together, the data support the
statement that at least 15 million polio survivors are alive
worldwide and that the percentage of polio survivors developing
PPSmay varywidely from20% to75%depending on the criteria used
for diagnosis and on the age of the groups investigated.
Figure 2 gives the estimated numbers of polio survivors in the
USA with age distributions for the years 2006 and 2016. The data
were obtained from the morbidity and mortality reports made to
public health authorities by the United States Public Health Service
(USPHS) taking into account life-expectancy. Numbers of polio
survivors are probably underestimated, since many polio cases are
underreported (mild or non-paralytic cases, cases treated outsideurvivors developing PPS. An estimate is provided for the whole world based on
(paralytic and
s)
% Polio
survivors
Reported prevalence of PPS among
polio survivors (% range)
1.74 20–45
0.07 68–78
0.08 20–40
0.21 14–60
0.09 10–45
0.12 15–55
0.13 15–75
0.02 50–85
0.15 14–85
0.08 25–80
0.10 Not available
0.15 50–80
0.20 25–40
0.05 30–60
0.21 Not available
orld-population-data-sheet_eng.pdf.
[(Figure_2)TD$FIG]
Figure 2. Predicted age distribution of polio survivors in the USA in the years
2006 and 2016 (source: Becker LC. Polio survivors in the U.S., 1915–2000. Age
distribution data. Saint Louis, MO: Post-Polio Health International; 2006).
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access to physicians, and rare cases among immigrants). In fact, the
National Center for Health Statistics (NCHS, of the Centers for
Disease Control and Prevention), on analyzing data collected
through the US Census Bureau process (1994–95), estimated the
numbers to be higher (774 500 in 2006 and 573 000 in 2016). The
trend indicates that inWestern countries, future treatmentswill be
directed at the ageing population, predominantly those in the age
range of 60–80 years. In contrast, the youngest and largest
proportion of these survivors reside in developing countries, and a
disproportionate number of these are female.86
8. Pathogenesis of PPS
Pathological descriptions of PPS have been scarce and have
emphasized the presence of persistent or new inﬂammation in the
meninges, spinal cord, and muscles of affected patients.87–92 At
variance with amyotrophic lateral sclerosis, no ubiquitin-reactive
inclusion bodies are present in anterior horn cells of PPS cases.90[(Figure_3)TD$FIG]
Figure 3. Idealized representation of changes inmotor units from the time of acute poliov
ﬁbres and loss of motor units accompanies the appearance of new weakness and the aAxonal spheroids in anterior horns and moderate Wallerian
degeneration in lateral columns have been reported.91 Postmortem
studies of 70 years ago documented frequent and severe
poliovirus-induced lesions within the reticular activating system
located in the brain stem that controls basic functions, including
sleep, waking, and behavioural motivation.93 In PPS patients,
magnetic resonance imaging has revealed small discrete or
multiple punctate areas of hyperintense signal in the reticular
formation, putamen, medial lemniscus, or white matter tracts in
55% of the subjects reporting high fatigue and in none of those
reporting low fatigue.93 Thus, lesions in these areas might
contribute to the generalized fatigue proper of PPS. The
inﬂammatory changes found mainly in the spinal cord and in
muscle suggest different pathogenic hypotheses, including persis-
tent poliovirus infection, autoimmune attack on the central and
peripheral nervous systems, and increased vulnerability of
poliovirus-damaged tissue to further infectious events. In subjects
with PPS, motor units are enlarged and symptoms are likely due to
degeneration and dysfunction of terminal axons.94
8.1. Distal degeneration hypothesis
Following the original observation of Wiechers and Hubbell in
polio patients,95 Emeryk et al. reported the progressive disinte-
gration of the motor units in individuals who were developing
PPS.96 A combination of distal degeneration of enlarged motor
units due to increased metabolic demands and the normal aging
process, as well as the ongoing inﬂammatory processes, were
thought to be involved.97 The most likely aetiology of new
weakness is the distal degeneration of the abnormally enlarged
motor units that form after poliomyelitis. This results in patchy
denervation of muscle ﬁbres (Figure 3). The denervated muscle
ﬁbres may become reinnervated from surviving motor neurons,
producing a continuous ‘remodelling’ of the motor unit. In
longitudinal studies with macro electromyography (macro-
EMG), a continuous loss of neurons has been demonstrated, with
exaggerated speed compared to normal age-dependent degenera-
tion.98 New weakness appears when reinnervation mechanisms
are no longer sufﬁcient and occurs when macro motor unit
potential (MUP) exceeds 20-times the normal size. Macro-MUP
amplitudes have been shown to be smaller in post-polio muscles
with new weakness and atrophy than in stable post-polio
muscles.99
8.2. Autoimmunity and co-factors
Currently, there is no evidence for PPS being an immune-
mediated condition. Levels of immune complexes are normal in
PPS patients,100 and no autoantibodies to CNS or muscle tissuesirus attack and the possible development of PPS. Distal degeneration of innervating
trophy of previously unaffected muscles.
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biomarker of Guillain–Barre´ syndrome) have not been detected.101
However, other CNS autoantibodies have not been adequately
investigated in PPS. For instance, antibodies to receptors, ion
channels, glutamic acid decarboxylase (GAD),102 and neuronal
surface antigens103 require appropriate research. Numerical
alterations in peripheral blood CD4 T-cells have been
reported,104,105 but T-cell autoreactivity and the immunoregulato-
ry functions of lymphoid cells have not been explored. Human
macrophages and dendritic cells are susceptible to PV infection.106
Some data have suggested that the numbers of regulatory T-cells in
PPS are increased as compared to non-polio controls.104
8.3. Persistent poliovirus infection in polio survivors and PPS
In the 1990s, a series of studies attempted to clarify whether
PVs could establish a persistent infection in some polio survivors.
The hypothesis was suggested by the ﬁnding of oligoclonal IgM
bands of PV antibodies in the cerebrospinal ﬂuid (CSF) of PPS
patients, but none in controls.107 The results supported the
intrathecal production of anti-polio antibodies, hence a continuous
infection within the CNS. Other investigators challenged the
data.108,109 Muir et al. used PCR assays directed at the 50-UTR
region of enteroviruses and investigated a cohort of PPS patients. It
was shown that a small percentage of PPS patients had enterovirus
RNA in the CSF, together with PV-speciﬁc oligoclonal IgM bands.110
The results strongly pointed to persisting infection, at least in a few
PPS patients. Using different PCR assays, positivity for PV genomes
was conﬁrmed in CSF and peripheral leukocytes,38 as well as in CSF
by others.39 In 1999, Julien et al. concluded that ‘PV genome
fragments’ were detectable in a signiﬁcant percentage of PPS
patients.40 Based on the above ﬁndings, an observational studywas
started in a cohort of polio survivors who were attending hospitals
in northern Italy, looking for new weakness and neuromuscular
problems. The results of virology studies (detection of poliovirus
genome and biological effects of the persisting virus) showed that
in polio survivors diagnosed with PPS, a low-level infection is
sustained by either PV1, PV2, or PV3 (not by non-polio
enteroviruses).41,111–113 Additional evidence has shown that
family members of PPS patients do not carry PV genomes, thus
conﬁrming that PPS patients are not infectious. So far, it has not
been possible to completely sequence the PV genome and to
demonstrate that the persisting virus plays a role in the
development of this progressive disorder. Novel technologies will
possibly help clarify the nature of PV genomes found in PPS
patients.
9. Possible treatments
The effectiveness of pharmacological treatment and the
management of rehabilitation in PPS is not yet established. A
meta-analysis has been conducted of randomized and quasi-
randomized trials of any form of pharmacological or non-
pharmacological treatment for people with PPS.21 The primary
outcome was self-perceived activity limitations, and secondary
outcomes were muscle strength, muscle endurance, fatigue, pain,
and adverse events. Nine pharmacological studies (modaﬁnil,
intravenous human immunoglobulin (IVIg), pyridostigmine, lamo-
trigine, amantadine, prednisone) and three non-pharmacological
studies (muscle strengthening, rehabilitation in warm or cold
climates, static magnetic ﬁelds) were examined. Due to issues with
the quality of the data and the lack of randomized studies, it was
not possible to draw deﬁnite conclusions on the effectiveness of
these interventions for PPS. However, treatment with IVIg,
lamotrigine, muscle strengthening exercises, and static magnetic
ﬁelds may be beneﬁcial.9.1. Intravenous human immunoglobulin (IVIg)
Over the last decade, several trials have explored the potential
of a single IVIg course for PPS patients. Immunoglobulin infusions
of 1–2 g/kg have been used. Patients have been evaluated at time
0 and at 2 to 12months post-treatment for a variety of parameters:
health-related quality of life (Short Form 36), Physical Activity
Scale for the Elderly, pain intensity (visual analogue scale), Six-
Minute Walk Test, and muscle strength. Results have varied
somewhat among trials, but patients have reported a reduction of
pain,114 an increased quality of life at 6 months (pain, vitality,
social function, and role emotional),115 and, in the ﬁrst months of
treatment, improvements in the mental component score.116 Age
<65 years, paresis in the lower extremities, and lack of
concomitant disorders may represent indicators for identifying
responders. A further study showed that up to 1 year after
treatment, concentrations of IFN-g and IL-23 were reduced in the
CSF of PPS patients, while those of the anti-inﬂammatory IL-13
cytokine were increased.65 Taken together, the results support a
beneﬁcial effect of a single IVIg course. Anecdotal reports of
repeated IVIg courses conﬁrm this conclusion.
What mechanisms of action form the basis of IVIg efﬁcacy? The
Fc fragment and the constant domain of the Fab fragment contain
binding sites for activated complement fragments, such as C3a,
C5a, C3b, and C4b. The interaction may prevent binding of
complement fragments to their receptors on target cells, thus
attenuating the immune damage.117 Fc sialylation of a small
percentage of human IgG has also been proposed as an anti-
inﬂammatory factor. Although glycosylation may not be so critical
for IVIg activity, results for the Guillain–Barre´ syndrome suggest
that sialylation is associated with improved clinical outcomes.
Antiviral antibodies may represent a further contributing factor.
For instance, in the experimental infection of mice with West Nile
virus (WNV), encephalitis and inﬂammation are prevented, in part,
by IVIg infusion (likely via anti-inﬂammatory activity). Interest-
ingly, humanWNV convalescent serumhas been shown to bemore
effective than IVIg in controlling encephalitis.118
9.2. Anti-poliovirus drugs
In 2005, the National Research Council Panel of the US National
Academies was invited to consider the development of antiviral
drugs to conclude the polio eradication effort.119–121 It was
thought that the development of at least two drugs active on
distinct targets was required. The primary application of anti-polio
drugs would be for the resolution of chronic poliovirus excretion in
persons with primary immunodeﬁciency, but the control of
possible polio outbreaks post-eradication and the sporadic
treatment of accidental exposure would represent additional
goals.121 In Europe, the FP6-supported project VIZIER was set up to
investigate enzymes involved in viral replication and to develop
speciﬁc inhibitors.122 In Japan, a successful effort was started to
control the possible zoonotic spread of foot-and-mouth disease
virus. An important compound, favipiravir, effective against
multiple RNA viruses, was developed.123 As shown in Table 3,
the numerous anti-polio drugs derived from these studies are
directed at a variety of targets.32,34–36,121–132
So far, only a few compounds have entered clinical develop-
ment, but no drugs have yet been approved for the treatment of
enterovirus infections. Monoclonal antibodies have recently been
added to the anti-polio armamentarium. Human and chimpanzee
monoclonals capable of neutralizing wild-type and vaccine PV
strains have become available.32,34,35,133 In transgenic mice
expressing the receptor PVR, small doses of select monoclonals
have been shown to provide pre- and post-exposure protection
from challenge with a lethal dose of poliovirus. The treatment of
Table 3
Candidate antivirals for the treatment of poliovirus infections
Compound Target Effective dose in
vitro or in animals
Clinical
development
for PV infection
Reference
Pirodavir-related compounds:
BTA39, BTA188
Capsid inhibitor. Interferes with binding to receptor and
uncoating
Nanomolar No 124
Pocapavir (V-073) Capsid inhibitor. Binds to VP1. Interferes with binding to
receptor and uncoating
Nanomolar Yes 121
H1PVAT Capsid inhibitor. Binds to VP1 in the pocket underneath the
ﬂoor of the capsid canyon involved in capsid binding
Nanomolar Yes 125
Substituted ﬂavanoids: 3(2H)-
isoﬂavene, 6-chloro-3(2H)-
isoﬂavene
Possible capsid inhibitors. Bind to capsid protein site Micromolar No 126
Amiloride Docks in the VPg-binding site of 3D RNA polymerase and
inhibits initiation of RNA synthesis
Micromolar No 127
GPC-N114 (2,20-[(4-chloro-1,2-
phenylene)bis(oxy)]bis(5-nitro-
benzonitrile))
Non-nucleoside inhibitor of 3Dpol targeting the RNA
template-primer binding site in the core of 3Dpol
Micromolar No 128
Favipiravir (T-705) Is phosphoribosylated by cell enzymes to a triphosphate
compound. Inhibits RNA-dependent RNA polymerase of
many different viruses
Nano/micromolar No 123
Seven potential inhibitors of RNA
polymerase
Block 3D polymerase initiation of RNA synthesis. However,
do not inhibit NTP binding during elongation
Micromolar No 122
Thiazolobenzimidazoles Interfere with 2C (helicase, ATPase) functions and inhibit
RNA replication
Micromolar No 129
TTP-8307 Binds to 3A protein (possible membrane anchor) and
inhibits RNA replication
Nanomolar No 129
Enviroxime-like compounds (A4,
E5, E7, GW5074)
Interfere with the processing of viral polyprotein affecting
both 3C- and 2A-dependent cleavage
Micromolar No 130
AG-7404 Inhibits the viral 3C protease. Synergistic with capsid
inhibitors
Nanomolar Yes 131
OSW-1 (candidate antitumor drug) Interferes with the human oxysterol-binding protein Nanomolar No 132
Poliovirus-neutralizing
chimpanzee/human monoclonal
antibodies
Six neutralizing antibodies active against vaccine and
virulent strains of polioviruses
5mg/mouse No 34
Poliovirus-neutralizing human
monoclonal antibodies 12F8 and
1E4
Neutralizing antibodies active against vaccine and virulent
strains of polioviruses
5mg/ml Pre-clinical
development
35
Chimpanzee monoclonal antibody
capable of neutralizing both PV1
and PV2
Extended-spectrum neutralizing antibody directed to the
capsid site that recognizes the cellular receptor
5mg/ml and
25mg/mouse
Pre-clinical
development
32,36
Single-domain antibody fragments
(VHHs) against PV-1
Interfere with virus attachment to cell, viral uncoating,
induce aggregation of virus–VHH complexes
Nanomolar No 133
PV, poliovirus; VP1, viral protein 1; VPg, viral protein genome-linked; 3Dpol, poliovirus RNA-dependent RNA polymerase; NTP, nucleotide triphosphate; VHHs, variable
domains of heavy chain antibodies.
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to the polio vaccine.36 This suggests that human monoclonals
could be used in combination with polio vaccine and/or drugs to
improve their efﬁcacy and to prevent the emergence of resistant
variants. These experimental data provide a proof of concept for
initiating the clinical evaluation of these biological products.
Anti-polio drugs can be grouped as follows: (1) capsid inhibitors
(interfere with virus binding to cellular receptor(s) and with the
uncoating process), (2) inhibitors of RNA-dependent RNA poly-
merase, (3) inhibitors of 2C helicase/ATPase, (4) inhibitors of the
lipophilic 3A protein, (5) inhibitors of PV proteases, (6) ligands of
human oxysterol-binding protein, and (7) PV neutralizing mono-
clonal antibodies (whole antibody or single-domain antibody
fragment).
9.3. Ongoing clinical trials
The design of therapeutic studies in patients with PPS raises
methodological concerns due to the multiform nature of this
progressive disease.134 Registered clinical trials in PPS patients are
currently underway (http://www.who.int/ictrp/search/en/; date of
consultation: 2015-03-16). A multicenter interventional, double-
blind, randomized, and placebo-controlled trial involving 10 coun-
tries aims to evaluate whether monthly IVIg infusions for 1 year issuperior to placebo, and to determine the effective IVIg dose.
Efﬁcacy is being measured simply as the physical performance of
the subjects in a 2-minwalking test. A second trial aims to compare
the potential of a microprocessor-controlled orthosis vs. a stance
orthosis in individuals with impairments of the lower extremities.
The physical performance of subjects is being assessed with a 6-
min walking test together with measurements of oxygen
consumption. Other trials are observational in nature. These aim
to deﬁne the reproducibility of the Six-Minute Walk Test that is
used tomeasure the physical performance of PPS subjects, the type
of mental fatigue in polio survivors, and the swallowing and facial
impairments in PPS patients.
Among current trials, the largest one is in the promising area of
IVIg treatment. The trial is based on a human IVIg preparation
whose IgG molecules have been shown to be functional both in Fc
fragment assays and in neutralization assays against polioviruses
and other pathogens.135 Since during production, IgG fractions are
exposed to multiple inactivation treatments, including nanoﬁltra-
tion, this IVIg preparation has wide margins of biological safety.
As of today, no experimental work or clinical trials have
attempted to assess the efﬁcacy of anti-polio compounds or
antibodies in curing PPS or in preventing its development. It is our
hope that this review will stimulate translational medicine to ﬁnd
a cure for this prevalent, progressive, and disabling disease.
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